Détail de la notice
Titre du Document
Acetato de glatiramero en pacientes con esclerosis múltiple remitente-recurrente no respondedores al interferón beta
Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis
Auteur(s)
OREJA-GUEVARA C. ; BERMEJO P. E. ; MIRALLES A. ; ...
Résumé
Introduction and objective. There are 4 immunomodulator treatments approved as first line therapy for patients with relapsing-remitting multiple sclerosis (RRMS). The objective of this study is to assess if glatiramer acetate (GA) is useful or not in patients who have discontinued interferon β (IFNβ) due to a suboptimal response or adverse events. Methods. This is an observational and retrospective study in RRMS patients who discontinued IFNβ therapy (2.9±2.4 years of treatment) and switched to GA (1.9± 1.4 years). They were classified in 2 groups depending on the reason for discontinuation: suboptimal response or side effects. In both treatments we analysed number of relapses, treatment duration and causes of discontinuation. Results. We included 58 patients of which 20 discontinued IFNβ for lack of effectiveness whereas 38 were due to adverse events. Patients who discontinued for suboptimal response changed from 1.38 ± 0.95 relapses per year with IFNβ to 0.52±0.86 with GA. Patients who discontinued for adverse events changed from 0.33 ± 0.64 relapses per year with IFNβ to 0.37±0.79 with GA. Conclusions. GA can be considered a good alternative treatment for MS patients with a suboptimal response or adverse events with IFNβ which confirms the existence of different mechanisms of action in both drugs.
Editeur
Doyma
Identifiant
ISSN : 0213-4853
Source
Neurología (Barcelona. Ed. impresa) A. 2009, vol. 24, n° 7, pp. 435-438 [4 pages]
Langue
Espagnol
Pour les membres de la communauté du CNRS, ce document est autorisé à la reproduction à titre gratuit.
Pour les membres des communautés hors CNRS, la reproduction de ce document à titre onéreux sera fournie sous réserve d’autorisation du Centre Français d’exploitation du droit de Copie.

Pour bénéficier de nos services (strictement destinés aux membres de la communauté CNRS (Centre National de la Recherche Scientifique), de l'ESR français (Enseignement Supérieur et Recherche), et du secteur public français & étranger) :